|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.65 EUR | -1.28% |
|
-3.26% | +9.43% |
Business description: Orion Oyj
- innovative medicines (43%): for the treatment of cancer and pain management;
- generic, OTC and biosimilar drugs (29.3%);
- branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- veterinary products (7.5%);
- pharmaceutical ingredients and outsourcing services (3.6%).
Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%).
Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Number of employees: 4,132
Sales by Activity: Orion Oyj
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Pharmaceuticals | 1.04B | 1.34B | 1.19B | 1.54B | 1.89B |
Geographical breakdown of sales: Orion Oyj
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Other Europe | 354M | 398M | 366M | 431M | 530M |
North America | 89.7M | 335M | 174M | 369M | 481M |
Finland | 316M | 326M | 334M | 348M | 366M |
Other Markets | 141M | 142M | 173M | 232M | 323M |
Scandinavia | 141M | 139M | 142M | 163M | 190M |
Executive Committee: Orion Oyj
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 2022-10-31 | |
René Lindell
DFI | Director of Finance/CFO | 50 | 2024-04-30 |
| Chief Operating Officer | 46 | 2021-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 64 | 2019-12-31 |
Sinikka Markkula
CTO | Chief Tech/Sci/R&D Officer | - | 2011-01-31 |
Composition of the Board of Directors: Orion Oyj
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2017-03-21 | |
Hilpi Rautelin
BRD | Director/Board Member | 65 | 2017-03-21 |
Kari Jussi Aho
BRD | Director/Board Member | 66 | 2020-05-05 |
| Chairman | 65 | 2024-03-19 | |
Karen Sörensen
BRD | Director/Board Member | 64 | 2022-03-22 |
Henrik Stenqvist
BRD | Director/Board Member | 59 | 2024-03-19 |
Minna Maasilta
BRD | Director/Board Member | 40 | 2026-03-23 |
Sophie Papa
BRD | Director/Board Member | 50 | 2026-03-23 |
Holdings: Orion Oyj
| Name | Stocks | % | Valuation |
|---|---|---|---|
ORION OYJ 0.4% | 440,944 | 0.4% | 37 M $ |
Company details: Orion Oyj
Group companies: Orion Oyj
| Name | Category and Sector |
|---|---|
ORION Pharma GmbH
 ORION Pharma GmbH Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets human and veterinary medicines |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.28% | -3.26% | +4.19% | +90.40% | 11.2B | |
| -2.33% | -2.09% | +50.33% | +162.29% | 1,060B | |
| -0.82% | -2.30% | +62.97% | +61.11% | 619B | |
| -0.73% | -4.98% | +27.22% | +84.46% | 438B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 333B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 267B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 218B | |
| -0.06% | -2.88% | +20.98% | +61.70% | 196B | |
| -3.72% | -1.10% | +13.35% | +71.53% | 161B | |
| Average | -0.93% | -3.25% | +22.38% | +59.00% | 358.51B | |
| Weighted average by Cap. | -0.57% | -2.96% | +35.18% | +81.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ORNBV Stock
- Company Orion Oyj
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition